Europe Point-Of-Care Molecular Diagnostics Market Size & Outlook
- Clinical Diagnostics
- Cancer Diagnostics
- Point-of-Care Molecular Diagnostics Market Outlook
- Cancer Diagnostics
Global Market
Related Markets
Ask Prism AI anything about the point-of-care molecular diagnostics market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
Europe point-of-care molecular diagnostics market highlights
- The Europe point-of-care molecular diagnostics market generated a revenue of USD 2,163.8 million in 2024.
- The market is expected to grow at a CAGR of 6.8% from 2025 to 2033.
- In terms of segment, infectious diseases was the largest revenue generating application in 2024.
- Oncology is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2033.
Europe data book summary
| Market revenue in 2024 | USD 2,163.8 million |
| Market revenue in 2033 | USD 3,906.4 million |
| Growth rate | 6.8% (CAGR from 2025 to 2033) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Oncology |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
| Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.3% of the global point-of-care molecular diagnostics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,183.0 million by 2033.
The increasing prevalence of chronic diseases, along with an increasing demand for rapid diagnostics in the region, are some key factors driving the market growth. Furthermore, government initiatives toward the development of point-of-care diagnostics equipment are expected to fuel market growth. In addition, the launch of new products drives the growth of the market in the review period.
In July 2021, QuantuMDx Group Limited, a UK-based developer of advanced point-of-care diagnostics, introduced its Q-POC system - a rapid, PCR-based point-of-care diagnostic system. The system and its first test, a SARS-CoV-2 detection assay, have received CE-IVD marking under the In Vitro Diagnostics Directive (98/79/EC), allowing its use in Europe.
Q-POC is a portable PCR system that condenses an entire molecular diagnostic laboratory into a user-friendly, accessible, and cost-effective single device, providing quick molecular diagnostic results at the point of care within approximately 30 minutes. The system is designed to be utilized by front-line healthcare professionals and can be employed in various settings, including emergency rooms, ICUs, birthing centers, clinics, and pharmacies. This development aims to enhance accessibility and efficiency in point-of-care testing for healthcare providers and patients.
No credit card required*
Publish Date: Aug 05, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Point-Of-Care Molecular Diagnostics Market Scope
Point-Of-Care Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Nova Biomedical | View profile | 501-1000 | Waltham, Massachusetts, United States, North America | www.novabio.us |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Nipro Corp | View profile | 39,713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | www.nipro.co.jp |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
Europe Point-of-Care Molecular Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Point-of-Care Molecular Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Infectious Diseases was the largest segment with a revenue share of 50.03% in 2024.
Horizon Databook has segmented the Europe point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2021 to 2033.
The increasing prevalence of chronic diseases, along with an increasing demand for rapid diagnostics in the region, are some key factors driving the market growth. Furthermore, government initiatives toward the development of point-of-care diagnostics equipment are expected to fuel market growth. In addition, the launch of new products drives the growth of the market in the review period.
In July 2021, QuantuMDx Group Limited, a UK-based developer of advanced point-of-care diagnostics, introduced its Q-POC system - a rapid, PCR-based point-of-care diagnostic system. The system and its first test, a SARS-CoV-2 detection assay, have received CE-IVD marking under the In Vitro Diagnostics Directive (98/79/EC), allowing its use in Europe.
Q-POC is a portable PCR system that condenses an entire molecular diagnostic laboratory into a user-friendly, accessible, and cost-effective single device, providing quick molecular diagnostic results at the point of care within approximately 30 minutes. The system is designed to be utilized by front-line healthcare professionals and can be employed in various settings, including emergency rooms, ICUs, birthing centers, clinics, and pharmacies. This development aims to enhance accessibility and efficiency in point-of-care testing for healthcare providers and patients.
- Europe Point-Of-Care Molecular Diagnostics Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Prenatal Testing
- Endocrinology
- Other Applications
- Hematology
- Infectious Diseases
- Europe Point-Of-Care Molecular Diagnostics Market Technology Outlook (Revenue, USD Million , 2021-2033)
- PCR-based
- Genetic Sequencing based
- Hybridization based
- Microarray based
- Europe Point-Of-Care Molecular Diagnostics Market Test Location Outlook (Revenue, USD Million , 2021-2033)
- OTC
- POC
- Europe Point-Of-Care Molecular Diagnostics Market End-use Outlook (Revenue, USD Million , 2021-2033)
- Decentralised Labs
- Hospitals
- Home care
- Assisted Living Healthcare Facilities
- Others
Reasons to subscribe to Point-of-Care Molecular Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Point-of-Care Molecular Diagnostics Market Outlook databook
- Our clientele includes a mix of Point-of-Care Molecular Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Point-of-Care Molecular Diagnostics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Point-of-Care Molecular Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Point-Of-Care Molecular Diagnostics Market, 2021-2033 (US$M)
Europe Application - Point-of-care Molecular Diagnostics Market Statistics, 2024 - 2033 (US$M)
